A secretagogue is any substance that triggers a cell to release something it has produced, whether that’s a hormone, an enzyme, a neurotransmitter, or another chemical. The term comes up most often in conversations about insulin, growth hormone, and digestive health, but it applies broadly across the body. Your stomach lining, your pancreas, your pituitary gland, and your adrenal glands all respond to secretagogues, both natural ones your body makes and synthetic ones developed as medications.
How Secretagogues Work Inside Cells
Secretagogues don’t create new substances. They signal cells to release what’s already been made and stored. The specificity of a secretagogue depends on its molecular shape and the receptors it binds to on or inside the target cell. A secretagogue for insulin, for example, won’t trigger the release of stomach acid because the receptors involved are completely different.
At the cellular level, secretagogues generally work through one of two pathways. The first involves calcium: the secretagogue binds to its receptor, which causes calcium ions to flood into the cell, and this calcium surge triggers the cell to push its stored contents out through a process called exocytosis. The second pathway involves a signaling molecule called cyclic AMP, which activates a chain of enzymes that ultimately cause the cell to release its stores. These two pathways are functionally separate. A secretagogue that mobilizes calcium won’t raise cyclic AMP levels, and vice versa.
The term “stimulus-secretion coupling” describes this entire process, from the moment a secretagogue hits a receptor to the moment the cell releases its cargo. It was coined by researcher W.W. Douglas based on his work studying the adrenal gland and pituitary gland.
Natural Secretagogues in Your Body
Your body produces its own secretagogues as part of normal physiology. Ghrelin is one of the best-known examples. This 28-amino-acid peptide is released primarily from the stomach and acts as a secretagogue for growth hormone, stimulating the pituitary gland to release it. Ghrelin levels rise before meals and drop afterward, which earned it the nickname “hunger hormone.” Its name actually derives from “ghre,” a root in ancient Proto-Indo-European languages meaning “grow,” reflecting its role in stimulating growth hormone.
Ghrelin also stimulates appetite by acting on nerve cells in the hypothalamus, the brain’s appetite control center, where it triggers the release of other hunger-promoting signals. It’s the only known gut peptide that increases appetite rather than suppressing it.
In the digestive system, gastrin is a key natural secretagogue. Released by cells in the stomach lining when you eat, gastrin triggers parietal cells in the stomach to produce hydrochloric acid. It also stimulates nearby cells to release histamine, which further amplifies acid production. On top of that, gastrin acts on cells in the pancreas to release digestive enzymes. So a single meal sets off a cascade of secretagogue activity across multiple organs.
Insulin Secretagogues for Diabetes
The most common medical use of the word “secretagogue” involves diabetes treatment. Insulin secretagogues are medications that stimulate the pancreas to release more insulin, and they fall into two main classes.
Sulfonylureas work by closing potassium channels on the surface of insulin-producing beta cells in the pancreas. When these channels close, the cell membrane’s electrical charge shifts, calcium rushes in, and the cell releases its stored insulin. This mechanism is effective at lowering blood sugar, but it works regardless of whether blood sugar is actually high at the time. That’s why the primary risks of sulfonylureas are hypoglycemia (blood sugar dropping too low) and weight gain. The 2025 American Diabetes Association guidelines specifically flag these risks in older adults, who are more vulnerable to dangerous blood sugar drops.
Meglitinides work through the same potassium channel mechanism but with a key difference: they bind to the receptor and release from it much faster. This makes them short-acting, so they primarily lower blood sugar spikes after meals rather than keeping insulin elevated all day. Because post-meal blood sugar spikes are independently linked to cardiovascular risk, meglitinides were developed partly to target that specific window.
Growth Hormone Secretagogues
Growth hormone secretagogues are compounds that stimulate the pituitary gland to release growth hormone. They work by mimicking ghrelin’s action at the ghrelin receptor. The most well-known synthetic version is ibutamoren (also called MK-0677 or LUM-201), a small-molecule drug that binds the ghrelin receptor and is being evaluated for conditions related to growth hormone deficiency, appetite disorders, and problems with gastric emptying.
Interestingly, some synthetic growth hormone secretagogues are actually more potent than ghrelin itself. Research published in Molecular Pharmacology found that ibutamoren and other synthetic compounds function as direct agonists at the ghrelin receptor with higher efficacy than the body’s own ghrelin. They bind to the same site on the receptor, not a separate one, and simply activate it more strongly.
Secretagogues vs. Agonists
You might see “secretagogue” and “agonist” used in overlapping ways, which can be confusing. An agonist is any substance that activates a receptor. A secretagogue is defined by its outcome: it causes a cell to secrete something. Many secretagogues are agonists, because they activate a receptor that leads to secretion. But not all agonists are secretagogues, since receptor activation can lead to many different cellular responses beyond secretion.
In the growth hormone field, these terms blur together because the synthetic growth hormone secretagogues happen to work by acting as agonists at the ghrelin receptor. They bind the receptor, activate it, and the downstream result is growth hormone release. So the same compound is accurately described as both a secretagogue (it causes secretion) and an agonist (it activates a receptor).
Secretagogues in Diagnostic Testing
Doctors also use secretagogues as diagnostic tools. The secretin stimulation test is a good example. Secretin is a hormone that, in healthy people, has a modest effect on gastrin levels. But in patients with gastrin-secreting tumors (gastrinomas, the hallmark of Zollinger-Ellison syndrome), injecting secretin causes an exaggerated spike in gastrin. A jump of more than 120 pg/mL above the baseline is considered a positive result.
This test is particularly valuable because it can detect gastrinomas even when fasting gastrin levels appear normal. In a retrospective study of patients with a genetic condition that predisposes them to these tumors, the secretin stimulation test identified abnormal gastrin responses in 75% of patients whose baseline gastrin levels were within the normal range. That early detection window can be critical for treatment timing.
Where Secretagogues Fit in Modern Medicine
Insulin secretagogues remain widely prescribed for type 2 diabetes, though their role has shifted as newer drug classes have emerged. GLP-1 receptor agonists and SGLT2 inhibitors now offer blood sugar control with added cardiovascular and kidney benefits, and some evidence suggests they may even slow cognitive decline. Sulfonylureas and meglitinides are still used, particularly when cost is a factor, but they’re less likely to be first-line choices than they were a decade ago.
Growth hormone secretagogues are still largely in clinical evaluation rather than routine use. Synthetic ghrelin receptor agonists like ibutamoren are being studied for a range of conditions, but they haven’t yet achieved widespread approval for most of these uses. You may encounter growth hormone secretagogues marketed as supplements online, but these products are not the same as the pharmaceutical compounds being tested in clinical trials and are not regulated to the same standard.